Research in my group centers on the regulation of the innate immune response in chronic airway diseases, such as cystic fibrosis (CF) and asthma, with a special focus on persistent NF-kB activation.

My laboratory was the first to describe a lack of the NF-kB regulator A20 in CF, which is highly correlated with lung function in these patients. Further studies are under way to identify regulators of A20. We apply bioinformatics to identify drugs already licensed for use in humans to regulate the immune response.